Cassava Sciences

SAVA

Biotech

Health Care

Meme

+1

Country

US

Industry

Health Care

Market Cap

Small Cap

Num. Employees

26

IPO Date

Jul 14, 2000

Create Alert

SAVA

Country

US

Industry

Health Care

Biotech

Health Care

+2

Create Alert

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 26 full-time employees. The company went IPO on 2000-07-14. The firm is engaged in the detection and treatment of neurodegenerative diseases, such as Alzheimer’s disease. The firm develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The firm has two biopharmaceutical assets under development, including its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer’s disease dementia, which is under Phase III clinical studies; and its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. Simufilam is a proprietary small molecule (oral) drug, which targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).